Chapter·PathologyNeoplasia

Characteristics of benign vs malignant tumorsDownloads

10Questions
10Flashcards
3Tables & Flowcharts

Study Materials

Practice

Sample Questions

1

A researcher is studying the ability of breast cancer cells to metastasize. Neoplastic cells obtained from 30 patients with stage IV ductal carcinoma of the breast are tagged with a fluorescent antibody. The cells are then inserted into a medium resembling normal human tissue. After 2 weeks, all samples show in vitro hematogenous invasion and migration away from the original site of insertion. Which of the following properties is most likely responsible for the ability of these neoplastic cells to metastasize?

ALoss of cellular polarity

BPresence of fibrous tissue capsule

COverexpression of HER2/neu

DIncrease in N:C ratio

ERelease of matrix metalloproteinase

2

A 56-year-old woman presents to a physician for evaluation of a lump in her left breast. She noticed the lump last week while taking a shower. She says that the lump seemed to be getting larger, which worried her. The lump is not painful. The medical history is unremarkable. She has smoked cigarettes for the last 30 years. On examination, bilateral small nodules are present that are non-tender and immobile. A mammography confirms the masses and fine needle aspiration cytology of the lesions reveals malignant cells arranged in a row of cells. What is the most likely diagnosis?

AFibroadenoma

BMucinous carcinoma

CInflammatory carcinoma

DInvasive lobular carcinoma

EInvasive ductal carcinoma

3

A research team develops a new monoclonal antibody checkpoint inhibitor for advanced melanoma that has shown promise in animal studies as well as high efficacy and low toxicity in early phase human clinical trials. The research team would now like to compare this drug to existing standard of care immunotherapy for advanced melanoma. The research team decides to conduct a non-randomized study where the novel drug will be offered to patients who are deemed to be at risk for toxicity with the current standard of care immunotherapy, while patients without such risk factors will receive the standard treatment. Which of the following best describes the level of evidence that this study can offer?

ALevel 1

BLevel 3

CLevel 5

DLevel 4

ELevel 2

+ 7 more in the PDF

More Neoplasia downloads

Browse all chapters

View all